Literature DB >> 3526559

Management of chronic myelogenous leukemia.

J D Griffin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3526559

Source DB:  PubMed          Journal:  Semin Hematol        ISSN： 0037-1963            Impact factor:   3.851


× No keyword cloud information.
  3 in total

1.  Randomized study on the treatment of chronic myeloid leukemia (CML) in chronic phase with busulfan versus hydroxyurea versus interferon-alpha.

Authors:  R Hehlmann; B Anger; D Messerer; R Zankovich; L Bergmann; H J Kolb; P Meyer; U Essers; U Queisser; H Vaupel
Journal:  Blut       Date:  1988-02

2.  Interferon alfa-2c in chronic myelogenous leukemia (CML): hematologic, cytogenetic and molecular-genetic response of patients with chronic phase CML previously resistant to therapy with interferon gamma.

Authors:  F Herrmann; D Jonas; S G Helfrich; A Lindemann; E Schleiermacher; R Mertelsmann
Journal:  Blut       Date:  1990-10

3.  Treatment of chronic myelogenous leukemia with recombinant interferon alfa-2b.

Authors:  N Niederle; O Kloke; D May; R Becher; R Osieka; C G Schmidt
Journal:  Invest New Drugs       Date:  1987       Impact factor: 3.850
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.